You are here: Industry Insights > pneumonia

News List

FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) drugs
June 04, 2019
FDA Approves Zerbaxa (ceftolozane and tazobactam) 3g Dose for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP).
Prescribed opioids raise risk of pneumonia europeanpharmaceuticalreview
January 09, 2019
A study has found that opioids, including morphine, codeine and fentanyl increase the likelihood of patients being affected by pneumonia…
Pfizer Initiates for 20-Valent Pneumococcal Conjugate Vaccine Phase 3 Program americanpharmaceuticalreview
December 17, 2018
Pfizer announced the initiation of a Phase 3 program for its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, for the prevention of invasive disease and .....
Artificial intelligence accurately diagnoses eye diseases and pneumonia europeanpharmaceuticalreview
February 28, 2018
Using AI and machine learning techniques, researchers have developed a new computational tool to screen patients with common retinal diseases, potentially speeding diagnoses and treatment…
Pfizer renews 'Know Pneumonia' campaign with myth-busting creative fiercepharma
November 09, 2017
Pfizer has relaunched its “Know Pneumonia” disease awareness campaign with a myths-and-facts approach.
New vaccine offers hope for pneumonia europeanpharmaceuticalreview
October 23, 2017
Scientists are developing a vaccine by targeting strains of S. pneumoniae…
Indian patent office grants patent to Pfizer for Prevnar 13 expressbpd
August 23, 2017
The granting of this patent would block other manufacturers in India from supplying this vaccine
Antibiotic therapy for nearly 1 in 4 adults with pneumonia does not work europeanpharmaceuticalreview
May 26, 2017
Approximately one in four (22.1%) adults prescribed an antibiotic in an outpatient setting (such as a doctor’s office) for community-acquired pneumonia does not respond to treatment, according to a new study.
Pfizer’s Phase III study to treat hospital-acquired pneumonia a success europeanpharmaceuticalreview
April 26, 2017
Positive results of Pfizer‘s REPROVE study showed that patients diagnosed with hospital-acquired pneumonia (HAP)...

Previous page 1 2 3 4 5 Next page